Criticism of secret reimbursement amounts in the Medical Research Act: Pharmaceutical costs on the rise

Veröffentlicht:

Von:

In this article, Dr. Carola Reimann, CEO of the AOK federal association, the secret reimbursement amounts in the Medical Research Act. It warns of cost increases and non -transparency and criticizes that medicines without relevant additional benefits become even more expensive. The new regulations endanger the affordability of the supply and serve above all company interests. This lazy compromise puts a strain on the solidarity community and contradicts the goal of a sustainably financed GKV system. Instead of economic development, the contributions of the care would have to be used. Read more on this topic in this article from Berlin.
In this article, Dr. Carola Reimann, CEO of the AOK federal association, the secret reimbursement amounts in the Medical Research Act. It warns of cost increases and non -transparency and criticizes that medicines without relevant additional benefits become even more expensive. The new regulations endanger the affordability of the supply and serve above all company interests. This lazy compromise puts a strain on the solidarity community and contradicts the goal of a sustainably financed GKV system. Instead of economic development, the contributions of the care would have to be used. Read more on this topic in this article from Berlin. (Symbolbild/MB)

Reimann for the MFG: Temporary secret prices and holey guardrails are a lazy compromise

The CEO of the AOK federal association, Dr. Carola Reimann, has sharply criticized the secret reimbursement amounts in the Medical Research Act (MFG). Despite warnings of rising costs and a lack of transparency, the traffic light is expected to decide on secret prices. The new regulation was provided with more requirements, but at the same time the AMNOG guidelines were softened. This makes medicinal products even more expensive without additional benefits, and the excessive prices can be veiled by the secret prices. In view of the billions of contributions that are issued in favor of an industry with above -average returns, this is extremely questionable.

In Germany, no functioning price brakes in Germany should no longer apply to medicinal products without additional benefits in Germany. This is confusing, since the price regulation was only introduced in 2022 to contain the exploding expenses in the area of ​​drugs. The fact that the same government, which has decided these regulations, now withdraws in significant parts shows a lack of compass of the traffic light.

The present compromise is complicated and susceptible to strategic use. The regulations could put a considerable burden on the SHI and lead to considerable additional expenses. Instead of having an eye on the affordability of care for the insured, company interests and location issues were rated higher. Politicians store business development at the expense of the SHI, in view of the lack of financing options.

A sustainably financed GKV system would guarantee stable social security contributions and certainly do more for German industry-and thus also for the pharmaceutical location of Germany-than the proposed regulations that go at the expense of the solidarity community. The contributions should be intended for the supply and not for the pharmaceutical location policy. Unfortunately, however, this will now happen.

The criticism of Dr. Carola Reimann draws attention to the problematic aspects of the Medical Research Act (MFG) and the effects on health care in Germany. The article illustrates the possible negative consequences of the secret reimbursement amounts and the softening of the AMNOG guidelines. It is also emphasized that a sustainably financed GKV system could ensure better care and a stronger German industry. This article wants to raise awareness of the effects of the MFG and stimulate a broader discourse on the priorities in health policy.